1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism.

Bioorg Chem

School of Pharmacy & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China; State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China. Electronic address:

Published: April 2023

The PI3K/AKT/mTOR signaling pathway is one of the most common abnormal activation pathways in tumor cells, and has associated with multiple functions such as tumor cell growth, proliferation, migration, invasion, and tumor angiogenesis. Here, a series of 3-amino-1H-indazole derivatives were synthesized, and their antiproliferative activities against HT-29, MCF-7, A-549, HepG2 and HGC-27 cells were evaluated. Among them, W24 exhibited the broad-spectrum antiproliferative activity against four cancer cells with IC values of 0.43-3.88 μM. Mechanism studies revealed that W24 inhibited proliferation by affecting the DNA synthesis, induced G/M cell cycle arrest and apoptosis by regulating Cyclin B1, BAD and Bcl-xL, meanwhile induced the change of intracellular ROS and mitochondrial membrane potential in HGC-27 cells. Moreover, W24 inhibited the migration and invasion of HGC-27 cells by decreasing EMT pathway related proteins and reducing the mRNA expression levels of Snail, Slug and HIF-1α. Furthermore, W24 displayed low tissue toxicity profile and good pharmacokinetic properties in vivo. Therefore, 3-amino-1H-indazole derivatives might serve as a new scaffold for the development of PI3K/AKT/mTOR inhibitor and anti-gastric cancer reagent.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2023.106412DOI Listing

Publication Analysis

Top Keywords

hgc-27 cells
12
migration invasion
8
3-amino-1h-indazole derivatives
8
w24 inhibited
8
cells
5
1h-indazoles derivatives
4
derivatives targeting
4
targeting pi3k/akt/mtor
4
pi3k/akt/mtor pathway
4
pathway synthesis
4

Similar Publications

PAMAM/miR-144 nanocarrier system inhibits the migration of gastric cancer by targeting mTOR signal transduction pathway.

Colloids Surf B Biointerfaces

January 2025

Affiliated Huishan Hospital of medical College, Yangzhou University,Wuxi Huishan District People's Hospital, Wuxi, Jiangsu Province 214187, China. Electronic address:

Exogenous microRNA-144 (miR-144) is considered as a potential biological drug for gastric cancer because of its biological activity to inhibit the epithelial-mesenchymal transition (EMT). However, the specific molecular mechanisms have not been fully revealed. In addition, their vulnerability to degradation by RNA enzymes in the blood limits their bioavailability.

View Article and Find Full Text PDF

Objectives: To investigate the expression of cartilage acidic protein 1 (CRTAC1) in gastric cancer (GC) and its effect on biological behaviors and immune cell infiltration of GC.

Methods: Transcriptomic, GO and KEGG analyses were conducted to investigate the association of CRTAC1 expression with prognosis of GC patients and its involvement in cell function and signaling pathways. ESTIMATE algorithm was used to analyze the effect of CRTAC1 expression on the tumor microenvironment and the tumor mutation load.

View Article and Find Full Text PDF

Identification of gastric cancer stem cells with CD44 and Lgr5 double labelling and their initial roles on gastric cancer malignancy and chemotherapy resistance.

Cell Biol Toxicol

December 2024

Department of General Surgery, First Medical Center of Chinese, PLA General Hospital, Haidian District, No.28 Fuxing Road, Beijing, 100853, China.

Accumulating evidences have indicated that cancer stem cells (CSCs) can initiate tumor progression and cause recurrence after therapy. However, specific markers of gastric CSCs (GCSCs) from different origins have not been comprehensively revealed. Here, we further detected whether cell populations labelled with CD44 and Lgr5, well-recognized stem markers for gastric cancer (GC), can better emphasize cancer initiation, therapeutic resistance and recurrence.

View Article and Find Full Text PDF

Cell Type-Preferential Expression of Peptidylarginine Deiminase 4 and p53-Dependent Therapeutic Vulnerabilities in Gastric Cancer.

Dig Dis Sci

December 2024

The State Administration of Traditional Chinese Medicine Key Laboratory of Toxic Pathogens-Based Therapeutic Approaches of Gastric Cancer, Yangzhou University, 136 Jiangyang Avenue, Building 41, Room 301, Yangzhou, 225009, Jiangsu, China.

Background And Aims: Previous studies have demonstrated that peptidylarginine deiminase 4 (PAD4) functions as a suppressor, promoter, or both in cancer pathogenesis and therapeutic outcomes. Although PAD4 expression has been proposed to be one of the molecular features of gastric cancer (GC), the biological basis of PAD4 in GC progression and chemotherapy has not been formally established.

Methods: Cell type-preferential expression of PAD4 was analyzed in both preclinical and clinical models.

View Article and Find Full Text PDF

Synthesis, anticancer and antibacterial evaluation of novel spiramycin-acylated derivatives.

RSC Adv

December 2024

Key Lab of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, CAS Dalian 116023 China +86 411 84379539 +86 411 84379519.

Spiramycin and its derivatives are commonly used antimicrobials, and its derivative, carrimycin, has recently been found to have good anticancer potential. Here, we found that the 4''-OH of spiramycin can be selectively acylated, resulting in a series of novel spiramycin derivatives with a structure similar to carrimycin. Anticancer studies showed that most of the derivatives exhibited moderate to good anti-proliferative activity against four cancer cell lines, including HGC-27, HT-29, HCT-116 and HeLa, especially compound 14, which has the strongest activity against HGC-27 cells with an IC value of 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!